Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS

Add to watchlist

$53.7

-1.29

-2.36%

Market closed

Open in about 12 hours

+86.88%

month

+86.88%

quarter

+168.69%

year

Market Cap	2.02B
Enterprise value	N/A

P/E	-4.84
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	11.62
Price/Book	1.55
PEG ratio	N/A
EPS	-4.77

Revenue	57.83M
EBITDA	-153.18M
Income	-148.20M
Revenue Q/Q	1004.56%
Revenue Y/Y	108.22%

Profit margin	-240.51%
Oper. margin	-246.62%
Gross margin	96.3%
EBIT margin	-246.62%
EBITDA margin	-264.85%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Profit margin
Jun 2023	15.27M	-31.42M	-205.69%
Sep 2023	1.87M	-39.14M	-2092.36%
Dec 2023	13.07M	-41.90M	-320.45%
Mar 2024	27.61M	-35.73M	-129.39%

Tarsus Pharmaceuticals Financials Estimate

Q Y

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Analyst Estimates
Sep 2025	64.27M	-7.83M	-12.19%
Oct 2025	76.8M	-12.70M	-16.55%
Dec 2025	90.1M	-6.00M	-6.66%
Mar 2026	102.32M	2.34M	2.29%

Analysts Price target
Financials & Ratios estimates

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Debt to assets
Jun 2023	188927000	41.19M	21.81%
Sep 2023	268332000	54.66M	20.37%
Dec 2023	266224000	69.23M	26.01%
Mar 2024	349278000	74.06M	21.21%

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Cash Flow
Jun 2023	-23.82M	64.09M	510K
Sep 2023	-32.36M	47.36M	104.89M
Dec 2023	-39.33M	17.85M	19.76M
Mar 2024	-37.78M	-102.22M	108.77M

Tarsus Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Tarsus Pharmaceuticals
Employees

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Employee count
Aug 2023	87
Sep 2023	87
Oct 2023	87
Nov 2023	87
Dec 2023	87
Jan 2024	87
Feb 2024	87
Mar 2024	244
Apr 2024	244
May 2024	244
Jun 2024	244
Jul 2024	244

Tarsus Pharmaceuticals
Hedge Funds Holdings Q1 2023

36.92% -40.44%

of TARS is owned by hedge funds

44 -26

hedge funds hold TARS stock

9.08M -11.53M

shares is hold by hedge funds

TARS hedge funds holdings changes

Tarsus Pharmaceuticals
Insider Trading

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Insider trades (number of shares)
Period	Buy	Sel
Jan 2023	0	23634
Feb 2023	0	22000
Mar 2023	0	35327
Apr 2023	0	19589
May 2023	0	22841
Jun 2023	0	24843
Jul 2023	0	115300
Aug 2023	9506	8000
Sep 2023	0	8000
Oct 2023	0	9604
Nov 2023	0	24711
Dec 2023	1000	50252

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	27 Dec 2023	AZAMIAN BOBAK R. director, officer: President/CEO and Boar.. director, officer: President/CE..	Common Stock	8,000	$20.22	$161,760
Sale	20 Dec 2023	TREVEJO JOSE M. officer: CHIEF MEDICAL OFFICER officer: CHIEF MEDICAL OFFICER	Common Stock	2,252	$20	$45,040
Sale	20 Dec 2023	AZAMIAN BOBAK R. director, officer: President/CEO and Boar.. director, officer: President/CE..	Common Stock	9,443	$19.96	$188,482
Sale	20 Dec 2023	AZAMIAN BOBAK R. director, officer: President/CEO and Boar.. director, officer: President/CE..	Common Stock	30,557	$20.36	$622,141
Purchase	15 Dec 2023	GOLDBERG ANDREW D. director director	Common Stock	1,000	$18.96	$18,960
Option	2 Dec 2023	YARNO WENDY L director director	Common Stock	5,000	N/A	N/A
Option	2 Dec 2023	YARNO WENDY L director director	Restricted Stock Units	5,000	N/A	N/A
Sale	30 Nov 2023	WHITFIELD DIANNE C. officer: Chief Human Resources Officer officer: Chief Human Resources ..	Common Stock	8,355	$16.31	$136,270
Sale	30 Nov 2023	WAHL BRYAN officer: General Counsel officer: General Counsel	Common Stock	8,356	$16.31	$136,286
Option	29 Nov 2023	WHITFIELD DIANNE C. officer: Chief Human Resources Officer officer: Chief Human Resources ..	Common Stock	23,920	N/A	N/A

TARS insider trading transactions

Tarsus Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Application	Application ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS Filling date: 19 Jun 2019 Issue date: 11 Aug 2022	19 Jun 2019	11 Aug 2022
Application	Application SYSTEMIC ISOXAZOLINE PARASITICIDES FOR VECTOR-BORNE AND VIRAL DISEASE TREATMENT OR PROPHYLAXIS Filling date: 3 Apr 2020 Issue date: 26 May 2022	3 Apr 2020	26 May 2022
Application	Application PHARMACEUTICAL COMPOSITIONS FOR DEMODEX RELATED BLEPHARITIS AND EYELID CRUSTING Filling date: 7 Jan 2022 Issue date: 28 Apr 2022	7 Jan 2022	28 Apr 2022
Application	Application METHODS FOR TREATING OCULAR DEMODEX USING SPINOSAD FORMULATIONS Filling date: 16 Nov 2020 Issue date: 24 Feb 2022	16 Nov 2020	24 Feb 2022
Grant	Grant Utility: Isoxazoline parasiticide formulations and methods for treating blepharitis Filling date: 5 Mar 2021 Issue date: 14 Dec 2021	5 Mar 2021	14 Dec 2021
Application	Application ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS Filling date: 5 Mar 2021 Issue date: 1 Jul 2021	5 Mar 2021	1 Jul 2021
Application	Application ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS Filling date: 16 Nov 2020 Issue date: 18 Mar 2021	16 Nov 2020	18 Mar 2021
Application	Application ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS Filling date: 16 Nov 2020 Issue date: 18 Mar 2021	16 Nov 2020	18 Mar 2021
Grant	Grant Utility: Methods for treating ocular demodex using isoxazoline parasiticide formulations Filling date: 14 Dec 2018 Issue date: 17 Nov 2020	14 Dec 2018	17 Nov 2020

TARS patents

Tarsus Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 8 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 27 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 10 Nov 2023	Q3 2023 Earnings Call Transcript

TARS earnings call transcripts

Tarsus Pharmaceuticals
Executives

Insider	Age	Since	Compensation
Dr. Seshadri Neervannan Ph.D. (1968) Chief Operating Officer	57		$486,670
Mr. Leonard M. Greenstein (1976) Chief Financial Officer	49		$416,740

Tarsus Pharmaceuticals
Latest News

Tuesday, 24 December 2024
12:51	4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow	zacks.com
Sunday, 15 December 2024
14:00	Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks	seekingalpha.com
Wednesday, 4 December 2024
10:56	Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet	zacks.com
Monday, 18 November 2024
11:00	Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade	zacks.com
Wednesday, 13 November 2024
22:23	Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript	seekingalpha.com
18:31	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
08:30	Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors	globenewswire.com
Thursday, 7 November 2024
11:00	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?	zacks.com
Wednesday, 6 November 2024
16:30	Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024	globenewswire.com
Tuesday, 5 November 2024
08:30	Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer	globenewswire.com
Wednesday, 30 October 2024
07:41	Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains?	zacks.com
Thursday, 17 October 2024
08:30	Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%	globenewswire.com
Wednesday, 25 September 2024
17:00	Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024	globenewswire.com
Friday, 20 September 2024
15:17	Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations	seekingalpha.com
Wednesday, 28 August 2024
17:00	Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference	globenewswire.com
Tuesday, 20 August 2024
16:56	Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment	seekingalpha.com
Saturday, 10 August 2024
13:50	Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript	seekingalpha.com
Thursday, 8 August 2024
19:07	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
Monday, 29 July 2024
16:30	Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024	globenewswire.com
Wednesday, 29 May 2024
17:00	Tarsus to Participate in Upcoming Investor Conferences	globenewswire.com
Thursday, 9 May 2024
17:00	Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference	globenewswire.com
Wednesday, 8 May 2024
21:45	Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript	Seeking Alpha
18:40	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Monday, 6 May 2024
10:56	Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?	Zacks Investment Research
Wednesday, 1 May 2024
17:00	Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024	GlobeNewsWire
Monday, 8 April 2024
10:56	Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know	Zacks Investment Research
Monday, 1 April 2024
13:00	Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why	Zacks Investment Research
Thursday, 7 March 2024
20:03	Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name	Seeking Alpha
Wednesday, 6 March 2024
10:56	How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%	Zacks Investment Research
Tuesday, 5 March 2024
16:30	Tarsus to Participate at Upcoming Investor Conferences	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 12 May 2025

Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off
Seeking Alpha 5 Dec 2023

Celebrating Seeking Alpha's New Analysts - November 2023 Edition
Seeking Alpha 4 Dec 2023

Tarsus Pharmaceuticals: 3 Clinical Catalysts In The Next 4 Months, Xdemvy Launch Underway
Seeking Alpha 7 Nov 2023

Xdemvy: Tarsus' Leading Asset In A Multi-Billion Market Landscape
Seeking Alpha 6 Oct 2023

Rare Stock Picks In September 2023 - From 32 Discerning Analysts
Seeking Alpha 4 Sep 2023

Tarsus Pharmaceuticals: Worthy Of A Small Bet
Seeking Alpha 25 Jul 2023

Tarsus Pharma: Despite Dropping After FDA Approval, 2 Catalysts Still Remain
Seeking Alpha 24 Jan 2023

Tarsus Pharma: Excellent Data, Nice Execution, Unclear Market Potential

Frequently Asked Questions (FAQ)

What's the price of Tarsus Pharmaceuticals stock today?

One share of Tarsus Pharmaceuticals stock can currently be purchased for approximately $53.7.
When is Tarsus Pharmaceuticals's next earnings date?

Unfortunately, Tarsus Pharmaceuticals's (TARS) next earnings date is currently unknown.
Does Tarsus Pharmaceuticals pay dividends?

No, Tarsus Pharmaceuticals does not pay dividends.
How much money does Tarsus Pharmaceuticals make?

Tarsus Pharmaceuticals has a market capitalization of 2.02B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 32.42% to 17.45M US dollars.
What is Tarsus Pharmaceuticals's stock symbol?

Tarsus Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "TARS".
What is Tarsus Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Tarsus Pharmaceuticals?

Shares of Tarsus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Tarsus Pharmaceuticals's key executives?
Tarsus Pharmaceuticals's management team includes the following people:
- Dr. Seshadri Neervannan Ph.D. Chief Operating Officer(age: 57, pay: $486,670)
- Mr. Leonard M. Greenstein Chief Financial Officer(age: 49, pay: $416,740)
How many employees does Tarsus Pharmaceuticals have?

As Jul 2024, Tarsus Pharmaceuticals employs 244 workers.
When Tarsus Pharmaceuticals went public?

Tarsus Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 16 Oct 2020.
What is Tarsus Pharmaceuticals's official website?

The official website for Tarsus Pharmaceuticals is tarsusrx.com.
Where are Tarsus Pharmaceuticals's headquarters?

Tarsus Pharmaceuticals is headquartered at 15440 Laguna Canyon Road, Irvine, CA.
How can i contact Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals's mailing address is 15440 Laguna Canyon Road, Irvine, CA and company can be reached via phone at +94 94099820.

Tarsus Pharmaceuticals, Inc.

tarsusrx.com

Exchange:

NASDAQ

Full time employees:

244

Industry:

Biotechnology

Sector:

Healthcare

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

+94 94099820

15440 Laguna Canyon Road
Irvine, CA 92618

CIK: 0001819790
ISIN: US87650L1035
CUSIP: 87650L103